The effectiveness and safety of therapy of drugs Mexidol and Mexidol Forte 250 in patients with chronic brain ischemia

Author:
L.A. SCHEPANKEVICH^1,2, Yu.A. NIKOLAEV¹, E.V. TANEEVA³, M.A. PERVUNINSKAYA¹, M.S. SCHEPANKEVICH^1,2

¹Federal Research Center for Fundamental and Translational Medicine, Novosibirsk, Russia;
²Novosibirsk State Medical University of the Ministry of Health of the Russian Federation, Novosibirsk, Russia;
³State Novosibirsk Regional Clinical Hospital, Novosibirsk, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2021, Vol. 121, No. 10

Abstract:
Objective of the study. To study the efficacy and safety of sequential therapy with Mexidol administered intravenously by drip (500 mg once daily) for 14 days, followed by oral administration of Mexidol FORTE 250 at a dose of 250 mg 3 times daily for 60 days in elderly patients with chronic cerebral ischemia (CCI) associated with arterial hypertension and atherosclerosis. Material and methods. The open prospective observational study included 60 patients with an established diagnosis of CCI, confirmed by the results of neuroimaging. All patients underwent an examination with assessment of neuropsychological status (MoCA test), severity of asthenia (MFI-20 scale), emotional state (Hamilton Anxiety and Depression Scale), motor functions (Tinetti Formalized Clinical Scale for Assessing the Motor Activity of the Elderly). The effectiveness of the therapy was assessed using the quality of life questionnaire (SF-36). Results. The study results demonstrated the high efficacy and safety of sequential Mexidol therapy in relieving asthenic and emotional disorders, improving cognitive function, and enhancing patients' quality of life. The maximum effect was observed after completing the full course of therapy. High patient compliance and a low incidence of adverse events were demonstrated. Conclusion. Sequential intravenous Mexidol followed by oral administration of Mexidol FORTE 250 is an effective and safe treatment for patients with chronic cerebral ischemia. Key words: chronic cerebral ischemia, arterial hypertension, atherosclerosis, ethylmethylhydroxypyridine succinate, Mexidol, Mexidol Forte 250, cognitive impairment.